Performance Evaluations of the Abbott Alinity m Assay in Comparison with the Abbott m2000 Assay for Hepatitis B and Hepatitis C Viruses

• Published in: Laboratory Medicine and Quality Assurance Vol. 42; no. 3; pp. 150 - 155
• Main Authors: Yoo, Jaeeun, Son, Beom Se, Han, Eunhee, Yu, Gyong Gi, Lee, Seungok
• Format: Journal Article
• Language: English
• Published: 대한임상검사정도관리협회 30.09.2020
• Subjects: 임상병리학
• ISSN: 2384-2458; 2288-7261
• DOI: 10.15263/jlmqa.2020.42.3.150

Background: The quantification of the hepatitis B virus (HBV) or hepatitis C virus (HCV) is critical for the diagnosis and prognostic follow-up of the viral infection. The Alinity m assay is a recently developed, fully automated “random-access” system for quantitative molecular assays. The aim of this study was to verify the validity of the Alinity m assay by comparing its performance in HBV and HCV quantifications with the established Abbott m2000 HBV and HCV assays. Methods: The precision, linearity, limit of detection (LOD), correlation with the Abbott m2000 assay, and interference were evaluated. Results: The within-laboratory standard deviation ranged from 0.106 to 0.137 log IU/mL for HBV and from 0.073 to 0.097 log IU/mL for HCV, which was lower than the manufacturer’s specification of 0.25 log IU/mL, indicating good precision. Linearity was observed from 1.14 to 8.14 log IU/mL for the HBV assay and from 1.09 to 7.09 log IU/mL for the HCV assay. The LODs of HBV and HCV were 10 and 6.39 IU/mL, respectively, which were equivalent to or better than those claimed by the manufacturer. For comparative evaluation between Alinity m and m2000 assays, 142 HBV and 70 HCV samples were tested. The correlation test revealed a strong correlation for both markers, and the Passing–Bablok regression analysis did not reveal any significant deviation. Conclusions: The Alinity m assay demonstrated excellent performance for HBV and HCV quantifications with reduced hands-on time and a randomaccess format. KCI Citation Count: 0